Table 2. The effects of TMZ treatment on lean male hearts subjected to AHF (n = 6).

Treatment group	Heart rate (%)	Sig.	LVDevP (%)	Sig.
Control	210.13 ± 127.11	ns	1259.06 ± 485.90	** ***
TMZ at CAHF	28.26 ± 1.48		2204.29 ± 355.33
TMZ at RAHF	29.74 ± 2.23		6025.70 ± 654.65
Treatment group	LVEDP (%)	Sig.	LVESP (%)	Sig.
Control	201.85 ± 36.57	ns	211.06 ± 43.49	ns
TMZ at CAHF	160.23 ± 9.38		170.36 ± 11.07
TMZ at RAHF	158.26 ± 18.72		171.80 ± 24.07

Data represent the last ten minutes of the RAHF phase and expressed as a percentage of CAHF. Significance is expressed as **p<0.01; ***p<0.001 vs. TMZ (at RAHF). LVDevP: left ventricular developed pressure; LVEDP: left ventricular end diastolic pressure; LVESP: left ventricular end systolic pressure; CAHF: critical acute heart failure; RAHF: recovery acute heart failure; Sig.: significance; ns: not significant.